 NRx Pharmaceuticals NASDAQ: NRXP has announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients to receive Zyesami aviptadil upon a physicians prescription, with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who cannot participate in a clinical study. 